Recent Transactions

Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

Advising Mitsui Chemicals,  one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG

Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia,  the largest health insurance provider in the Kingdom of Saudi Arabia

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab